Talimogene laherparepvec in combination with cisplatin + radiotherapy in patients receiving first-line therapy for the treatment of locally advanced head and neck cancer

Trial Profile

Talimogene laherparepvec in combination with cisplatin + radiotherapy in patients receiving first-line therapy for the treatment of locally advanced head and neck cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Aug 2010

At a glance

  • Drugs Talimogene laherparepvec (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Sponsors BioVex
  • Most Recent Events

    • 02 Aug 2010 Results published today in Clinical Cancer Research, as reported in a BioVex media release.
    • 02 Aug 2010 Status changed from active, no longer recruiting to completed, as reported in a BioVex media release.
    • 02 Jun 2009 Results were presented at ASCO 2009, and in a BioVex media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top